Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service prostatectomy & nephrectomy cases in Massachusetts: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (203 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 15 | 1,016 | 28% |
| 2020 | 11 | 824 | 30% |
| 2021 | 18 | 982 | 32% |
| 2022 | 17 | 968 | 35% |
| 2023 | 11 | 933 | 38% |
| 2024 | 10 | 885 | 39% |
| 2025 from claims | – | 974 788–1,144 | 40% |
| 2026 forecast | – | 1,005 787–1,262 | 39% |
| 2027 forecast | – | 1,020 756–1,348 | 40% |
| 2028 forecast | – | 1,036 733–1,429 | 40% |
| 2029 forecast | – | 1,051 715–1,508 | 40% |
| 2030 forecast | – | 1,068 699–1,584 | 40% |
Robotic radical prostatectomy and laparoscopic nephrectomy. Professional codes (what the surgeon bills): CPT 55866, 50543, 50545, 50546, 50548; the hospital bills MS-DRG 707, 708, 656, 657, 658.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Massachusetts; 7 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 28% inpatient hospital, 72% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~1,000 | ~270 | ~740 |
| 2027 · ~1,000 | ~260 | ~760 |
| 2028 · ~1,000 | ~270 | ~770 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 74% (72% in 2025), inpatient hospital about 26% (28% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 33 | 2,271−2.4%/yr | −2.4%/yr | 1.4 | 0% | 2,710 in 2030+3%/yr |
| Pennsylvania | 27 | 1,659−0.2%/yr | −0.2%/yr | 1.3 | 0% | 1,900 in 2030+2.3%/yr |
| New Jersey | 9 | 867+0.5%/yr | +0.5%/yr | 0.9 | 0% | 1,060 in 2030+3.4%/yr |
| Connecticut | 4 | 324+1.3%/yr | +1.3%/yr | 1.1 | 0% | 480 in 2030+6.6%/yr |
| New Hampshire | 5 | 194−3.3%/yr | −3.3%/yr | 0.9 | 0% | 300 in 2030+7.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 93 | 4,315−1.9%/yr | −1.9%/yr | 4.60.8× | 8% | 4,690 in 2030+1.4%/yr |
| Hysterectomy, hysteroscopy & ablation | 41 | 3,182−0.5%/yr | −0.5%/yr | 3.61.1× | 17% | 3,720 in 2030+2.6%/yr |
| BPH procedures | 46 | 2,725−3.2%/yr | −3.2%/yr | 2.90.6× | 13% | 2,910 in 2030+1.1%/yr |
| Incontinence, prolapse & sacral neuromodulation | 30 | 1,885+3.7%/yr | +3.7%/yr | 2.01.1× | 1% | 2,140 in 2030+2.1%/yr |
Prostatectomy & nephrectomy in every state, and its device makers · Every procedure market in Massachusetts · Every state · Compare with New York
Intuitive Surgical leads with 100% of company spending on these surgeons in 2025, level with 2024.
In 2025, 2 companies reported engagement with Massachusetts’s surgeons worth $217K in consulting, speaking, meals and travel tied to these products, about $22K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 9 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.